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Abstract 
The use of sub-unit vaccines can solve some drawbacks associated with traditional 
attenuated or inactivated ones. However, in order to improve their immunogenicity, 
these vaccines needs to be associated to an appropriate adjuvant which, adequately 
selected, may also offer an alternative pathway for administration. The aim of this 
work was to evaluate the protection offered by the hot saline complex extracted from 
Brucella ovis (HS) encapsulated in mannosylated nanoparticles (MAN-NP-HS) when 
instilled conjunctivally in mice. Nanoparticles displayed a size of 300 nm and the 
antigen loading was close to 30 µg per mg nanoparticle. Importantly, encapsulated 
HS maintained its protein profile, structural integrity and antigenicity during and after 
the preparative process of nanoparticles. The ocular immunization was performed on 
BALB/c mice. Eight weeks after vaccination animals were challenged with B. ovis, 
and 3 weeks later, were slaughtered for bacteriological examinations. Animals 
immunized with MAN-NP-HS displayed a 3-log reduction in spleen CFU compared 
with unvaccinated animals. This degree of protection was significantly higher than 
that observed for the commercial vaccine (Rev1) subcutaneously administered. 
Interestingly, the mucosal IgA response induced by MAN-NP-HS was found to be 
much more intense that that offered by Rev1 and prolonged in time. Furthermore, the 
elicited IL-2, IL-4 and γ-IFN levels showed good correlation with the degree of 
protection. On the other hand, biodistribution studies in animals were performed with 
nanoparticles labelled with either 99mtechnetium or rhodamine B isothiocyanate. The 
biodistribution revealed that, after instillation, MAN-NP-HS moved from the palpebral 
area to the nasal region and, the gastrointestinal tract. This profile of distribution was 
different to that observed for free 99mTcO4- colloids, which remained for at least 24 
hours in the site of administration. In summary, mannosylated nanoparticles appear 
to be a safe and suitable adjuvant for conjunctival vaccination. 
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99mTc: 99mtechnetium 
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CFU: colony forming units 
DMF: dimethylformamide 
EE: entrapment efficiency 
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HS: hot saline subcellular complex extracted from Brucella ovis 
GALT: gut-associated lymphoid tissue 
MALT: mucosa-associated lymphoid tissue 
MAN-NP: mannosylated poly(anhydride) nanoparticles 
MAN-NP-HS: HS-loaded mannosylated poly(anhydride) nanoparticles 
NALT: nasal-associated lymphoid tissue 
PBS-T: solution of Tween 20 (0.05% w/v) in PBS 
RBITC: rhodamine B isothiocyanate 
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1. Introduction  
Brucellosis is a zoonotic infection transmitted from animals to humans by direct- or 
indirect contact with infected animals or their products such as the ingestion of raw 
milk and other unpasteurized dairy products (i.e. soft cheeses) [1, 2]. Other common 
routes of infection in humans include infection through cuts and abrasions, the 
conjunctival sac of the eyes or the inhalation of aerosols [3, 4]. In livestock, the main 
route of infection is via the sucking or licking of aborted foetuses and their placentas, 
as well as vaginal discharges. Infection due to the ingestion of infected milk or 
feedstuffs may also occur [1]. Human brucellosis remains the commonest zoonotic 
disease worldwide with more than 500,000 new cases annually [5]. Furthermore this 
infection is associated with substantial residual disability, and is an important cause 
of travel-associated morbidity [6]. 
Mass vaccination of animal populations accompanied by a strict surveillance scheme 
is a first step to reduce the number of infected animals and hence the infection 
pressure in regions where the incidence rate of animal brucellosis is high. The most 
commonly used vaccines are Brucella melitensis Rev1 and Brucella abortus S19 
vaccines [7]. B. abortus RB51 vaccine is also used in some countries [8]. 
The B. melitensis Rev1 strain is currently considered as the best vaccine available 
for the control of ovine and caprine brucellosis, especially when used at the standard 
dose by either the subcutaneous or the conjunctival routes [9, 10]. However, due to 
its live attenuated nature, Rev1 displays a large number of drawbacks, including 
residual virulence and interferences with serodiagnosis [8]. In order to solve some of 
these drawbacks, the use of sub-unit vaccines have been proposed such as the hot 
saline subcellular complex extracted from B. ovis (HS) [11]. However, due to its non-
replicant nature, adequate adjuvants have to be associated. In this context, poly(ε-
caprolactone) microparticles containing HS were found to be safe and effective in 
mice and ram models, when administered by the subcutaneous route [12, 13]. 
However, regarding the behaviour of Brucella during the infection and colonization 
processes, the delivery of the antigens (HS) through mucosal surfaces is of 
remarkable interest in order to both mimic the bacteria pattern and generate 
immunity at the major portals of entry for these microorganisms.  
Mucosal surfaces, mostly the subepithelial regions, are enriched in 
immunocompetent B and T lymphocytes, as well as antigen presenting cells (APCs). 
These cells are organized into the mucosa-associated lymphoid tissue (MALT) found 
in various sites of the body such as the gut (GALT), lung (BALT) or skin (SALT), 
among others [14]. In the eye, the conjunctiva, the palpebral area and the eye 
lachrymal drainage system are provided with an associated lymphoid tissue (termed 
CALT, conjunctiva-associated lymphoid tissue) [15] containing the specialized 
antigen sampling M-cells [16] present at other mucosal localizations, such as 
intestinal Peyer’s patches. Furthermore, evidences from many studies have 
confirmed the inter-connected mucosal system, known as common mucosa immune 
system, allowing that the stimulation at one mucosal site can lead to effector immune 
cells in local as well as distal mucosal surfaces [14]. In addition to these 
immunological reasons, mucosa vaccination can also be safer and easier to 
dispense than traditional (parenteral) vaccines [17, 18]. 
In the last years, nanoparticles made from the copolymer of methyl vinyl ether and 
maleic anhydride (Gantrez® AN) have demonstrated a remarkable capability to 
induce immune responses when administered orally [19-21]. This last property can 
be potentiated and modulated by the “decoration” of the surface of these 
poly(anhydride) nanoparticles with ligands capable to recognize and bind to specific 
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components of the MALT. Among other ligands, mannose and its derivatives may be 
of interest due to the capability of these compounds to link with mannose receptors 
highly expressed in cells of the mucosal immune system (i.e. macrophages and 
dendritic cells) [22, 23]. 
The aim of this work was to evaluate the protection offered by the HS-loaded 
mannosylated poly(anhydride) nanoparticles, when administered conjunctivally as 
eye drops, against experimental B. ovis infection in mice. Moreover, the 
biodistribution of these nanoparticles after their administration was evaluated. 
 
2. Material and Methods 
2.1. Chemicals 
Poly(methyl vinyl ether-co-maleic anhydride) or poly(anhydride) [Gantrez® AN 119; 
Mw 200 KDa] was gifted by ISP (Spain). Mannosamine hydrochloride, rhodamine B 
isothiocyanate (RBITC), concanavalin A and Tween 20 were purchased from Sigma-
Aldrich (Spain). Antibodies peroxidase/ conjugate anti-IgA were supplied from Nordic 
Immunol. Labs (The Netherlands). BCATM Protein Assay Reagent Kit was from 
Pierce (USA). Acrylamide Criterion XT Precast gels (18 Comb, 30 µL, 1 mm) were 
obtained from Bio-Rad Laboratories (USA). PVDF (pore size of 0.45 µm) sheets were 
from Schleicher & Schuell (Germany) and 4-chloro 1-naphtol from Merck (Germany). 
Blood Agar Base plates were from BioMérieux SA (France) and O.C.T.TM was 
obtained from Sakura (The Netherlands). RPMI 1640 media, β-mercaptoethanol, 
penicillin, streptomycin, FBS, sterile PBS and sodium pyruvate were purchased from 
Gibco-BRL (UK). 99Mo-99mTc generator was from Drytec (GE Healthcare, UK). 
Acetone, ethanol and dimethyl formamide (DMF) were obtained from BDH-
Prolabo/VWR (France). Stannous chloride, methylethylketone and potassium 
perchlorate, were from Panreac (Spain). T-61 was from Intevet (Spain) and the 
isoflurane (IsofloTM) from Esteve (UK). All other chemicals used were of analytical 
grade and obtained from Fluka (Spain).  
 
2.2. Extraction and characterization of the hot saline antigenic complex (HS) 
The hot saline antigenic complex (HS) was obtained from the strain B. ovis REO 198 
incubated in a bioreactor as described previously [24]. Total protein and 
lipopolysaccharide content of each batch of the antigenic extract were determined by 
the BCATM Protein Assay and the Warren modified method [24], respectively. The HS 
used to prepare the nanoparticles contained 66.4±10.6% total proteins and 
39.5±3.8% rough lipopolysaccharide.  
 
2.3. Preparation and labeling of nanoparticles  
2.3.1. Preparation of HS-loaded mannosylated nanoparticles 
Poly(anhydride) HS-loaded mannosylated nanoparticles (MAN-NP-HS) were 
prepared by the solvent displacement method as described previously [20, 25]. 
Briefly, four mg of the HS antigenic extract were dispersed in acetone an added to 
100 mg of Gantrez® AN 119 dissolved in acetone, previously incubated overnight 
with 1 mg of mannosamine. After 30 min of incubation, nanoparticles were formed by 
the addition of an ethanol/water mixture (1:1 v/v). Once the organic solvents were 
eliminated under reduced pressure (Büchi R-144, Switzerland), the aqueous 
nanosuspensions were magnetically stirred for 1 h with mannosamine. The resulting 
nanoparticles were purified twice at 3,000 x g for 20 min by centrifugal filtration in 
tubes VivaSpin® 20 300,000 MWCO (Vivascience, Germany). Filtrates were 
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collected for the quantification of HS and mannosamine. Finally, formulations were 
freeze-dried with sucrose at 5% as cryoprotector (Genesis 12EL, Virtis, USA).  
Control mannosylated nanoparticles (MAN-NP) were prepared using the same 
methodology without the use of HS. 
 
2.3.2. HS-loaded mannosylated nanoparticles labeled with RBITC  
HS-loaded nanoparticles were fluorescently labeled by incubation with 1.25 mg of 
rhodamine B isothiocyanate (RBITC) for 5 min at room temperature [20, 25]. After 
adsorption of the marker, the nanoparticles were purified by centrifugation and, 
finally, freeze-dried as described above. 
 
2.3.3. HS-loaded mannosylated nanoparticles labeled with 99mTc  
Nanoparticles were radiolabeled with 99mTc by reduction of 99mTc-Pertecnetate 
(99mTcO4-) with stannous chloride as described previously [26]. Briefly, 20 µL of a 
stannous chloride solution were added to 1 mg of freeze-dried nanoparticles followed 
by addition of 74 MBq of freshly eluted 99mTcO4- in 0.5 mL. The mixture was vortexed 
for 30 seconds and incubated at room temperature for 10 min. The pH of the final 
suspension was adjusted to 4.  
 
2.4. Characterization of nanoparticles  
2.4.1. Size, zeta potential, morphology and yield  
The size and zeta potential of the nanoparticles were determined by photon 
correlation spectroscopy and electrophoretic laser Doppler anemometry, 
respectively, using a Zetamaster analyser system (Malvern Instruments, UK). The 
yield of the nanoparticles preparation process was determined by gravimetry from 
freeze-dried nanoparticles as described previously [20]. 
The morphological characteristics of the nanoparticles were observed by electron 
microscopy in a Zeiss DSM 940A microscope (Oberkochen, Germany) coupled with 
a digital image system (Point Electronic GmBh, Germany). Previously, nanoparticles 
were diluted with deionised water and centrifuged at 17,000 rpm (Sigma 3K30, 
Germany) for 20 min. The pellet was dried and shaded with a 9 nm gold layer in a 
Emitech K 550 Sputter-Coater (Ashford, UK). 
 
2.4.2. Quantification of HS loaded in nanoparticles 
The HS loading in the nanoparticles was quantified by the BCATM Protein Assay 
method from the difference between its initial concentration added and the 
concentration found in the collected filtrates obtained during purification. Each 
sample was assayed in triplicate. To evaluate the effect of the manufacturing process 
on the HS protein integrity profile and antigenicity, proteins from the freeze-dried 
nanoparticles were extracted with a mixture of acetone and DMF (3:1, v/v) and 
assayed by SDS-PAGE and immunoblotting using sera from naturally infected rams 
with B. ovis [24]. 
 
2.4.3. Mannosamine content and agglutination assay 
The amount of mannosamine associated to nanoparticles was estimated by 
difference between the initial amount added and the amount quantified in the 
supernatants collected during the purification step of the preparative process [20]. In 
order to verify the activity of the mannosamine associated to the surface of 
nanoparticles an in vitro agglutination assay was performed. For this purpose 
mannosamine nanoparticles were dispersed in water and incubated with 
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concanavalin A. The turbidity changes were measured in a spectrophotometer at 405 
nm, as described previously [20].  
 
2.5. Protective effect of HS-loaded mannosylated nanoparticles 
Animal experiments were performed according to the policies and guidelines of the 
responsible Committee of the University of Navarra in line with the European 
legislation on animal experiments (86/609/EU) and following a protocol approved by 
the Ethic Committee of the University of Navarra. 
 
2.5.1. Ocular immunization and challenge with B. ovis  
The protective efficacy of HS-loaded nanoparticles against the virulent B. ovis PA 
strain was conducted in BALB/c mice, using the B. melitensis Rev1 vaccine as a 
reference. Twenty four female BALB/c mice (8 weeks old supplied by Harlan, Spain), 
were placed into rack conditions and divided in four groups. Animals were 
conjunctivally immunized with 8 µL of one of the following treatments administered in 
each eye: (i) 12 µg HS-loaded in mannosylated nanoparticles (MAN-NP-HS), (ii) 
empty nanoparticles (MAN-NP) equivalent to the dose administered in the first group, 
and (iii) sterile Buffered Saline Solution (BSS) as unvaccinated control group. As 
reference, Rev1 was subcutaneously administered once (5x105
 
CFU/mouse in 100 
µL BSS). Faecal IgA, antibodies against HS and γ-IFN, IL-2 and IL-4 cytokines (from 
spleen and lymph node cells) were determined.  
Eight weeks after vaccination, mice were challenged intraperitoneally with 5 x104
 
CFU/mouse of the virulent B. ovis PA reference strain. Three weeks after infection, 
animals were sacrificed by cervical dislocation, and the spleens were aseptically 
removed. Then, samples were individually homogenized in BSS, and properly diluted 
and plated in Blood Agar Base for viable counts. Plates were incubated for 3-5 days 
at 37±1 ºC in a 10% CO2 atmosphere. The protection level conferred by each 
preparation was expressed as the mean ± SD (n=6) of the CFU of the virulent 
challenge strain per spleen, after logarithmic conversion. 
 
2.5.2. Faecal specific IgA anti-HS  
Faecal samples from each group of mice were collected into microtubes and 
weighed. Non-fatty milk in PBS (3%) was added at a ratio of 1 mL/100 mg faecal 
pellets, vortexed for 5 min at room temperature and centrifuged at 10,000 x g for 10 
min. Supernatants were transferred to tubes containing 10 µL of protease inhibitor 
and stored at -20°C until use. Analysis of faecal samples was conducted as 
described elsewhere [29]. Briefly, HS-coated plates were blocked with 200 µL of 3% 
non-fatty milk in PBS-0.05% Tween 20 (PBS-T) for 1 h, at room temperature. Faecal 
extract samples of 100 µL diluted 1:2 in PBS-T were added and incubated at 37 ºC 
for 4 h. Finally, washed wells were treated with antibodies peroxidase/conjugated 
anti-IgA in a 1:1000 dilution. The detection was carried out with H2O2-ABTS and the 
absorbance was determined at λmax 405 nm. 
 
2.5.3. Cytokine assay 
Immunized animals were sacrificed 4 or 8 weeks after administration to remove 
spleens and lymph nodes (axillary, brachial, cervical and mesenteric). Isolated cells 
obtained as described previously [12] were stimulated with HS (100 μg) and cultured 
at 37ºC with 12% CO2 during 48 h for IL-2 and IL-4, and during 72 h for γ-IFN 
quantification. Released cytokines were determined with the correspondent 
commercial sandwich ELISA kit (BiosourceTM, USA). 
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2.5.4. Anatomopathological studies 
Accordingly to OECD 405 guidelines for the testing of chemicals (in vivo test for 
acute eye irritation/corrosion) [27], during the days following the instillation of 
nanoparticles, all the animals were inspected for local reactions. In addition, 1-day 
and 3-days after immunization, female BALB/c mice (n = 4) were sacrificed. Eye 
samples were fixed in 10% buffered formalin, embedded in paraffin and 4-5 μm 
sections were stained with haematoxylin-eosin (H&E stain) using standard 
procedures for microscopic examination. 
 
2.6. Biodistribution of nanoparticles 
The studies were performed after approval by the responsible Ethical Committee of 
the University of Navarra in strict accordance with the European legislation in animal 
experiments. 
 
2.6.1. Studies with fluorescently labeled nanoparticles  
A single dose of RBITC-labeled MAN-NP-HS containing 12 μg of HS in 8 µL water for 
injection was conjunctivally administrated in each eye of BALB/c mice. The animals 
were sacrificed 4 h later and the eyes, nose and portions from the gastrointestinal 
tract of about 0.5 cm length were removed and washed with PBS. Then, samples 
were treated with O.C.T.TM, frozen in liquid nitrogen and stored at -20 ºC. Tissue 
samples were cut into 5 µm longitudinal sections in a cryostat (2800 Frigocut E, 
Reichert-Jung, Germany), attached to glass slides and visualized by fluorescence 
microscopy (Olympus U-RFLT50, Japan).  
Additionally, two animals received one conjunctival dose per eye of 8 µL RBITC-
labeled MAN-NP-HS containing 12 μg of HS, and 4 h post-administration were 
euthanized with T-61 (after anaesthesia with 2% isoflurane), frozen in liquid nitrogen, 
treated with O.C.T.TM and stored at -20 ºC. Entire animals were then cut into 40 µm 
longitudinal sections in a cryostat (2800 Frigocut E, Reichert-Jung, Germany), 
attached to tap slides, and visualized with a fluorescence source and photographed 
(Olympus U-RFLT50, Japan).  
 
2.6.2. Studies with radiolabelled nanoparticles 
One hour before the ocular administration of HS-loaded nanoparticles as eye drops, 
animals were treated by the intravenous route with a solution of potassium 
perchlorate in saline (3 mg/kg). Then, animals received a single ocular dose of 8 µL 
containing 99mTc-MAN-NP-HS nanoparticles (2.37 MBq, 12 µg HS per eye) and were 
divided in two groups. The first group of animals was euthanized with T-61, at 4 h 
post-administration (as indicated above) frozen in liquid nitrogen, treated with 
O.C.T.TM and stored at -20 ºC. Entire animals were then sliced into 20 µm 
longitudinal sections in a cryostat (Bright 8250, Bright Instrument Co Ltd, UK), and 
exposed to digital autoradiography imaging plates (BAS-SR 2025, Fujifilm, Japan) for 
20 min. Then, the images were read in a digital autoradiography instrument and 
treated with the Raytest BAS500 reader 3.14 software (Fujifilm, Japan). The second 
group of animals was euthanized either 2- or 24-h after the administration of 
radiolabeled nanoparticles. Then, lymph nodes, stomach, small intestine, large 
intestine, spleen, liver, kidney, palpebral area, eyes and nose were collected, 
weighed, and the radioactivity of each organ was measured in a gamma counter 
(1282 Compugamma CS, LKB Pharmacia, Finland) calibrated for 99mTc energy. 
Results were expressed as counts per minute per gram of each organ divided by the 
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total counts per the total weight of the whole organs [(cpm/organ weight)/(total 
cpm/total weight]. In these studies a control group of animals receiving the equivalent 
dose of free technetium was used.  
 
2.7. Statistical analysis 
Data were expressed as the mean ± S.D. of at least three experiments. Statistical 
significance analysis was carried out using the non-parametric Kruskal-Wallis test, 
followed by Mann-Whitney U-test. P values of < 0.05 were considered as statistically 
significant. Calculations were performed using SPSS 16.0.1 software (USA). 
 
3. Results 
3.1. Physicochemical characterization of nanoparticles  
Table 1 summarizes the main physicochemical properties of nanoparticles used in 
this study. Mannosylated nanoparticles displayed a mean size of about 270 nm 
whereas the encapsulation of HS yielded higher nanoparticles (about 300 nm). The 
morphological analysis by scanning electron microscopy confirmed the presence of 
spherical particles with a similar size to that obtained by photon correlation 
spectroscopy (Figure 1). The presence of HS did not really affect the negative zeta 
potential of nanoparticles. Similarly, the yield of the preparative process and the 
homogeneity of the different batches prepared (polydispersity of about 0.2 ± 0.1) was 
found to be similar for both control and HS-loaded nanoparticles.  
The mannosamine content was found to be about 30 µg mannosamine per mg of 
nanoparticles. The agglutination test in the presence of the mannose-specific 
Concanavalin A confirmed the mannose integrity and activity after mannosylation of 
poly(anhydride) nanoparticles (data not shown). HS loading was calculated to be 28 
µg HS per mg of nanoparticles with an encapsulation efficiency close to 70%. The 
integrity and antigenicity of HS after its encapsulation in nanoparticles was evaluated, 
after extraction from the carriers, by SDS-PAGE and Western blot. In both cases, the 
protein profile of HS extracted from nanoparticles was similar to free HS, and the 
immunobloting demonstrated a similar reactivity against a pool of sera from B. ovis 
experimentally infected rabbits, showing that the antigenicity of the main proteins 
involved in infection was conserved (data not shown).  
 
Table 1. Physico-chemical characteristics of nanoparticles. MAN-NP: empty 
mannosylated poly(anhydride) nanoparticles; MAN-NP-HS: HS-loaded nanoparticles. 
Data expressed as mean ±SD, n=10. 
Formulation Size 
(nm) 
Zeta 
potential 
(mV) 
Yield 
(%) 
Man conten 
(µg/mg NP) 
HS loading 
(µg/mg NP) 
EE 
(%) 
MAN-NP 272±12 -38.2±1.4 81±6 30.2±4.1 - - 
MAN-NP-HS 306±11 -34.6±1.3 80±5 32.1±4.7 28.3±1.9 69±1 
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Figure 1. Scanning electron microscopy (SEM) microphotographs from a lyophilized 
sample of MAN-NP-HS.  
 
3.2. Mice immunization studies  
Figure 2 shows the levels of specific IgA against HS elicited at 4- and 8- weeks after 
immunization. The mucosal IgA response after immunization with HS-mannosylated 
nanoparticles was found to be intense and prolonged in time. Thus, 8-weeks post-
immunization, the faecal IgA elicited response was found to be 2-times higher for 
MAN-NP-HS than for Rev1.  
Figure 3 shows the levels of cytokines at 4- and 8- weeks after immunization with 
MAN-NP, MAN-NP-HS or Rev1, secreted from spleen cells or lymph nodes after in 
vitro stimulation with HS. MAN-NP-HS and Rev1 elicited similar responses and they 
showed significant differences from unvaccinated animals (p < 0.05) especially for γ-
IFN. Differences were higher with the spleen cells at the 8th week. In contrast, the 
highest values of cytokines secreted by cells from lymph nodes were obtained 4 
weeks post-administration.  
 
 
Figure 2. Faecal anti-IgA elicited by BALB/c mice after subcutaneous immunization 
with B. melitensis Rev1 or ocular immunization with empty mannosylated 
nanoparticles (MAN-NP) and HS-loaded mannosylated nanoparticles (MAN-NP-HS). 
Control: animals treated with BSS. * p < 0.01, Mann-Whitney U-test. 
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Figure 3. Cytokines secretion from spleen and lymph node cells after HS stimulus, 
elicited in BALB/c mice after immunization with B. melitensis Rev1 vaccine (Rev1), 
mannosylated nanoparticles (MAN-NP) or HS-loaded mannosylated nanoparticles 
(MAN-NP-HS). A: levels of IL-4; B: levels of IL-2; C: levels of gamma-interpheron. 
Data refers to values quantified 4 weeks (a) or 8 weeks (b) post-immunization.  
 
3.3. Protection studies 
Table 2 summarizes the bacteriological results obtained after challenge of the 
immunized mice with B. ovis PA strain. Mannosylated nanoparticles loaded with HS 
and conjunctivally administered as eye drops offered the highest degree of protection 
with respect unvaccinated control group (3.7 vs 6.6 Log CFU/spleen), even higher 
than that offered by the Rev1 vaccination by the subcutaneous route (p < 0.01).  
 
 
Table 2. Protective efficacy of HS-loaded mannosylated nanoparticles (MAN-NP-HS), 
conjunctivally administered, after challenge with the virulent Brucella ovis PA strain. 
MAN-NP: empty mannosylated nanoparticles, Rev1: B. melitensis Rev1 vaccine sc 
administered. Data expressed as mean and SD (n=6) of log CFU of B. ovis per 
spleen for each group of vaccinated and unvaccinated mice (control group).  
Immunization 
strategy 
Mean±SD 
Log (CFU/spleen) 
Statistical differences vs1 
MAN-NP MAN-NP 
HS 
Rev1 Control 
(BSS) 
MAN-NP 4.62±0.27 - A A A 
MAN-NP HS 3.69±0.13 - - A A 
Rev1 4.10±0.22 - - - A 
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Control (BSS) 6.62±0.21 - - - - 
1 Statistical differences between the immunized groups (non-parametric by Mann-Whitney U-test): A: p 
< 0.01 regarding the CFU/spleen of the animals  
 
3.4. Pathological studies 
After conjunctival immunization, animals were inspected for irritation symptom or 
lesions due to the instillation and presence of nanoparticles in the eyes. 
Macroscopically, neither ulceration nor opacity was observed in the cornea. 
Furthermore, the iris presented an apparently normal aspect with absence of 
chemosis. However, during the first 24 h after the administration of nanoparticles, 
some eyes displayed hyperaemic blood vessels and redness. In any case, since the 
animals did not develop apparent ocular damage, the study ended 3 days post 
instillation. 
Figure 4 shows microphotographs from the eyes of animals after the instillation of 
mannosylated nanoparticles. Compared with samples from animals treated with 
water for injections and which presented normal aspects (data not shown), eyes 
treated with nanoparticles displayed some inflammatory cells in the periphery of 
lymphoid follicles (CALT) and in the nictitating membrane (Figure 3A). In addition, 
some inflammatory cells, mainly neutrophils, could be observed into capillaries and 
perivascular tissue in the ciliary body of the eyes three days after immunization 
(Figure 3B and 3C). 
 
Figure 4. Histologic tissue sections of eyes from mice, 1 day (A) and 3 days (B and 
C) after instillation of mannosylated nanoparticles. A: presence of moderate numbers 
of lymphocytes and plasma cells at the periphery of a lymphoid follicle in the 
nictitating membrane CALT, (H&E stain, 400x) B: Mild inflammatory reaction of ciliary 
body (H&E stain, 100x); C: Detail of figure B showing neutrophils as the main 
component of the inflammatory infiltrate (H&E stain, 400x).  
 
3.5. Biodistribution studies of nanoparticles after ocular administration of 
fluorescent and radiolabeled nanoparticles 
In order to study the distribution of MAN-NP-HS after administration as eye drops, 
the nanoparticles were labeled with either RBITC or 99mTc. Figure 5A shows the 
distribution of RBITC in the body and in different organs of the animals 4 h after the 
ocular administration of a single dose of fluorescently labeled nanoparticles. RBITC 
was visualized in the eyes, nasal duct, stomach and intestine. From a microscopic 
study, it was possible to corroborate the presence of the fluorescent marker in the 
site of administration (cornea, conjunctive and lachrymal sac), but also at the nasal 
associated lymphoid tissue (NALT) and Peyer’s patches of the ileum of animals 
(Figure 6). 
This pattern of distribution was confirmed by autoradiography after radiolabeling of 
HS loaded mannosylated nanoparticles with 99mTc (Figure 5B). In this case, intense 
radioactivity was found in the ocular mucosa as well as in the gastrointestinal tract.  
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Figure 5. Fate of nanoparticles (MAN-NP-HS) fluorescently labeled with RBITC (A) or 
radiomarked with 99mTc (B), 4-h after their administration by instillation in the eyes of 
animals. Fluorescence is visualized in the eyes, nose, stomach and intestines of the 
animal (A). Mice autoradiograph shows radioactivity in the site of administration and 
the gastrointestinal tract (B). 
 
Figure 6. Visualization of RBITC, in different organs of the animals, 4-h after the 
instillation of MAN-NP-HS fluorescently labeled. (A) Cornea (magnification 100x); (B) 
Eye of animals (magnification 100x); (C) Nose sample (magnification 400x); (D) 
Intestinal Peyer patch (magnification of 400x).  
 
In order to confirm these results, ex vivo biodistribution studies were conducted. 
Radiolabeled nanoparticles were conjunctivally administered and animals were 
sacrificed either 2 or 24 h post administration. The different organs were recovered 
for measuring the radioactivity in a gamma-counter. Figure 7 summarizes these 
results. When free 99mTcO4- instead of 99mTc-radiolabeld nanoparticles was 
administered, radioactivity (around 80%) was mainly found in the palpebral area 
(lids). On the contrary, radiolabeled nanoparticles dramatically modified the 
biodistribution of the radioactive marker, and significant levels of radioactivity were 
found in the stomach, intestines, eyes and nose. Another important fact was that the 
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amount of radioactivity found in the animal’s stomach decreased with time, whereas 
it increased in the large intestine. 
 
Figure 7. Biodistribution studies of free 99mTcO4− (A) and 99mTc-labeled MAN-NP-HS 
(B). Animals were sacrificed either 2 or 24 hours post-conjunctival administration. 
The radioactivity of each organ was expressed as counts per minute per gram of 
each organ divided by the total counts per the total weight of the whole organs. Each 
value represents the mean ± SD of 3 animals. Legend: LN: lymph nodes; St: 
stomach; SI: small intestine; LI: large intestine; S: spleen; L: liver; K: kidney; PA: 
palpebral area (lids) and CALT; E: eye; N: nose and NALT; M: mouth.  
 
 
4. Discussion 
It is well known that the ocular bioavailability of drugs applied topically as eye-drops 
is typically poor. The absorption of drugs in the eye is limited by some protective 
mechanisms (i.e. lachrymation and tear turnover; drainage via the conjunctival sac) 
and other factors such as the limited corneal area and poor permeability. The 
drainage of the administered dose via the nasolachrymal system takes place when 
the volume of fluid in the eye exceeds the normal lachrymal volume. More important, 
the lachrymation and the physiological tear turnover are stimulated by the instillation 
of even mildly irritating fluids compromising bioavailability [28, 29]. Under these 
circumstances it appears that the induction of immune responses through instillation 
of a vaccine in the eye would be an important challenge.  
In this context, the aim of this work was to evaluate the protective effect of a new 
conjunctival vaccine against brucellosis based on the loading of the B. ovis HS 
antigenic complex in mannosylated poly(anhydride) nanoparticles. Mannosylation of 
nanoparticles was carried out in order to target mannose receptors, which are highly 
expressed in cells of the immune system (i.e. macrophages and dendritic cells) [30] 
and are involved in antigen capture and presentation [31]. The HS-loaded 
nanoparticles were obtained as a dry powder which was put easily in suspension by 
the addition of water. The dispersed nanoparticles displayed a size of about 300 nm 
with an antigen loading of about 30 µg HS per mg nanoparticle (Table 1). These 
nanoparticles displayed a relatively smooth surface (Figure 1). 
After the conjunctival administration of HS-loaded mannosylated nanoparticles high 
levels of specific mucosal IgA were detected (Figure 2). At the same time, this 
nanoparticle formulation induced high and similar levels of Th1 (γ-IFN and IL2) and 
Th2 (IL4) cytokines than the commercial Rev1 vaccine (Figure 3). Specifically, γ-IFN 
has been defined as a key actor in the cellular immune response necessary to 
eliminate intracellular bacteria, like Brucella [32, 33]. Thus, both effector components, 
mucosal anti-Brucella IgA and Th1 immunity would be directly related with the level 
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of protection conferred by MAN-NP-HS, even higher than that conferred by the Rev1 
vaccine (Table 2) [34, 35]. 
Interestingly, the conjunctival administration of MAN-NP-HS in mice did not induce 
significant levels of inflammatory cells post-immunization (Figure 4). With the 
exception of mild inflammatory perivascular infiltrates localized in the ciliary body of a 
mouse inoculated with nanoparticles, animals did not develop microscopic lesions in 
the eyes. All the components of the anterior chamber, cornea, iris, pupil, and the 
lens, optic nerve, nictitating membranes and bulbar conjunctiva lacked injuries and 
had a histologic normal appearance. This almost complete absence of injuries in all 
the ocular structures proves that instillations of mannosylated nanoparticles by ocular 
way in mouse are not-irritating to eyes and satisfy the OECD 405 guidelines for the 
testing of chemicals [27].  
The biodistribution study clearly shown that, after the instillation of nanoparticles in 
the eye, a fraction of these carriers remained in the site of administration whereas a 
significant percentage of the dose migrated to other areas of the body such as the 
nose mucosa and the gastrointestinal tract. Within the gut, labeled nanoparticles 
were mainly detected in the stomach and the intestine, including Peyer’s patches 
(see Figures 5 and 6). On the other hand, the distribution of free 99mTc-pertechnetate 
and 99mTc-radiolabeled nanoparticles was completely different. Free technetium was 
mainly detected in the palpebral area (lids), with slight detection in the stomach or 
other parts of the body (Figure 7).  
Interestingly, the profile of biodistribution of nanoparticles was independent of the 
type of labeling used, either fluorescent (rhodamine B isothyocyanate) or radioactive 
(99mTc). In fact, this distribution agrees well with the physiological mechanisms of 
clearance which protects the surface of the eye. In fact, the excess of liquid in 
contact with the surface of the eye, due to the lid movement, is drained through the 
conjunctival sac, the lachrymal sac and into the nasolachrymal duct into the nose. 
Then, from the nose, the liquids can easily reach the gastrointestinal tract [36].  
This profile of distribution of nanoparticles, when administered topically as eye drops, 
may be responsible for their ability to induce protective immune response. In fact, 
one portal of entry would permit to reach at least three different mucosal surfaces 
and, thus, induce simultaneous response against the pathogen in different effector 
sites of the body.  
 
5. Conclusions  
In summary, HS-loaded in mannosylated nanoparticles appears to be an interesting 
vaccine candidate when conjunctivally administered as eye drops. This efficacy 
would be related with their distribution after instillation. In fact, the excess of 
nanoparticle suspension, via the lachrymal drainage system, is capable to reach the 
nose and the gastrointestinal tract. In all of these mucosa nanoparticles can 
encounter APCs and, thus, induce and potentiate the immune response. 
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